tag:blogger.com,1999:blog-5574479.post5189823074629191364..comments2024-03-29T13:59:42.629+00:00Comments on The IPKat: F-word not descriptive of pharma product, rules courtVerónica Rodríguez Arguijohttp://www.blogger.com/profile/05763207846940036921noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-5574479.post-85080110828458442382016-12-07T08:46:49.128+00:002016-12-07T08:46:49.128+00:00....and here is the inevitable conclusion:
https:.......and here is the inevitable conclusion:<br /><br />https://www.gov.uk/government/news/cma-fines-pfizer-and-flynn-90-million-for-drug-price-hike-to-nhs<br /><br />Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-5574479.post-12126725718043152612015-10-14T16:23:19.430+01:002015-10-14T16:23:19.430+01:00Is this the same Flynn Pharma that, along with Pfi...Is this the same Flynn Pharma that, along with Pfizer, is currently being investigated for potential abuse of a dominant position in respect of its practices in relation to this product?<br /><br />See CMA press release, of 6 August 2015: "The Competition and Markets Authority’s (CMA) provisional view is that Pfizer and Flynn Pharma each abused a dominant position by charging excessive and unfair prices in the UK for phenytoin sodium capsules, an anti-epilepsy drug, in breach of UK and EU competition law."<br /><br />https://www.gov.uk/government/news/cma-issues-statement-of-objections-to-pfizer-and-flynn-pharma-in-anti-epilepsy-drug-investigationAnonymousnoreply@blogger.com